Teva offers to buy rival Mylan for $40 billion | Fortune
Teva Pharmaceutical Industries Ltd. ends its hostile bid for Mylan NV - Pittsburgh Business Times
Teva drops bid for Mylan, buys Allergan's generics unit | Pittsburgh Post-Gazette
Drugmaker Teva makes $40B bid for rival Mylan
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
How Mylan tried to keep Teva from selling a generic EpiPen
Generic drugmaker Teva makes $40bn offer for rival Mylan
Big blow for Teva as FDA approves Mylan's generic Copaxone - Globes
Mylan Should Try Teva On for Size - WSJ
Mylan Rejects $40-Billion Bid from Teva | Fox Business
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Teva gains leverage in pursuit of Mylan | Pittsburgh Post-Gazette
Teva Makes Hostile Bid To Acquire Mylan
US lawmakers push Mylan, Teva over drug pricing probe - www.israelhayom.com
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Israel-Based Teva Pharmaceutical Industries Smacks Down With Mylan With $40B Bid - YouTube
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva makes $40B offer for Mylan
Teva makes $40 billion offer for Mylan
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
